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RESEARCH ARTICLE
Phrenic nerve study as outcome in clinical trials for amyotrophic
lateral sclerosis
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Lisbon, Portugal 2Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar
Universitario de Lisboa Norte, Lisbon, Portugal
Abstract
Introduction: Respiratory tests are fundamental for monitoring respiratory function in ALS, and essential in clinical trials.
Slow vital capacity (SVC) was canceled in some countries to prevent COVID-19 transmission. We aimed to test phrenic
nerve motor responses as an option to SVC in clinical trials. Methodology: Patients followed-up in our unit were selected
respecting inclusion criteria used elsewhere: possible/probable/definite disease; onset-age 18–80years; disease duration
from disease duration 24months; body mass index (BMI)>20kg/m2; respiratory subscore of the revised ALS functional
rating scale (ALSFRS-R)11; upright SVC  70%. We added normal phrenic responses (meanPhrenAmpl, 0.4mV).
All patients were on riluzole. SVC and meanPhrenAmpl were recorded at study entry (T0) and 24 weeks later (T1).
Decays were determined. Sample size was calculated for a treatment effect of 30% on the decay rate. Results: We
included 317 ALS patients (191 males, 225 spinal-onset), mean onset-age 59.9±10.7 (31–80)years, mean onset BMI
25.48±3.2 (20.1–35)kg/m2, mean disease duration 10.5±5.6 (1–24)months, mean ALSFRS-R 41.54±4.3 (22–47) and
respiratory subscore 11.83±0.38 (11–12). MeanPhrenAmpl and SVC were weakly but significantly correlated at T0
and T1. At T1, MeanPhrenAmpl decayed 16.94±16.45% and SVC 13.5±16.86%. For the proposed drug effect, 174
and 272 patients would be needed to recruit using respectively meanPhrenAmpl and SVC decline as the primary out-
come measurement (accepting no dropouts). Discussion: Contrary to SVC, meanPhrenAmpl is non-volitional and not
associated with aerosolization risk. Lower recruitment number (98 patients less) would be needed, translating shorter
inclusion period, trial length and costs, and probable lower missed data rate. MeanPhrenAmp is an alternative test in
ALS clinical trials.
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Introduction
COVID-19 pandemic has risen many unthinkable
difficulties in the medical and research fields, in
particular affecting patients with chronic diseases
who need regular follow-up, as patients with
amyotrophic laterals sclerosis (ALS) (1). Technical
procedures were restructured or eventually can-
celed to prevent the virus transmission (2). ALS
patients using ventilatory support and with sus-
pected COVID-19 infection are recommended to
use face mask interfaces without expiratory valve,
in addition to filters intercalated in the system.
Forced (FVC) and slow (SVC) vital capacity, max-
imal pressures, as well as peak expiratory flow and
peak cough flow, are volitional respiratory function
tests (RFT) frequently used to monitor the respira-
tory function in ALS (3–6), which have been can-
celed in many ALS centers due to the risk of virus
transmission (7–8). The respiratory tests are fun-
damental to monitor the respiratory function in
ALS, indicating the need for ventilatory support
(3). In addition, their values are used as inclusion
criteria in trials, and their results accepted as a pri-
mary outcome measure (9).
The diaphragmatic motor responses by transcu-
taneous phrenic nerve stimulation is a noninvasive,
non-volitional test that uses surface electrodes to
record the diaphragmatic response (10). Contrary
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to the volitional RFT, it is usually performed with-
out asking the patient for any specific maneuver,
being the stimulus given at the end-expiration
phase to guarantee a consistent maximal relaxation
of the diaphragm (11). Previous studies have
shown that the responses by phrenic nerve stimula-
tion are reliable (12), symmetrical in ALS (13),
correlated with FVC (14), predictive of survival
(15), and hypoventilation both in spinal and bul-
bar ALS patients (10), as well of functional status
(16). It bypasses the major limitation that FVC/
SVC and other RFT face when assessing ALS
patients, which is the orofacial paresis (10). As a
non-volitional test that does not originate aerosol
particles, it can present itself as an alternative to
FVC/SVC during the COVID-19 pandemic.
With the present study we aimed to determine
if the phrenic nerve motor responses are appropri-
ate as inclusion criterion and outcome measure in
clinical trials as compared with SVC.
Methodology
Patients with possible, laboratory-supported prob-
able (Awaji guidelines), probable or definite ALS
in accordance with the revised El Escorial criteria
and with follow-up in our ALS center in Lisbon
were considered. The patients were followed pro-
spectively (before the COVID-19 pandemic), but
the analyses was done retrospectively.
Inclusion criteria required, following recent crite-
ria in clinical trials (9): age at onset between 18 and
80 years, disease duration from disease duration at
inclusion  24 months; body mass index (BMI) >
20kg/m2; respiratory subscore of the revised ALS
functional rating scale (ALSFRS-R)  11; upright
SVC 70% of the predicted value; mean peak-to-
peak amplitude of the bilateral phrenic motor
responses 0.4mV. All patients were stable on rilu-
zole 50mg bid, and none had been included in any
trial. We excluded patients with clinical signs of
dementia, with other forms of motor neuron disease
(primary lateral sclerosis, progressive muscular atro-
phy, flail-arm, flail-leg, Kennedy’s disease), and with
other medical disorders including asthma, chronic
obstructive pulmonary disease, diabetes, heart failure,
or polyneuropathy.
Slow vital capacity evaluation
SVC was determined with the patients in the sitting
position, by using a computer-based USB spirometer
(microQuarkVR , CosmedVR ) or standard Jager equip-
ment (two J€agerVR MasterlabVR , and one J€agerVR
MasterscreenVR , Erich Jager, GmbH, Wurzburg,
Germany). All measurements were performed by one
of the authors (SP), using microQuarkVR , CosmedVR ,
and the same technician for the J€ager equipment.
The best of three satisfactory and consistent expira-
tory maneuvers, each obtained after a maximal
inspiratory effort, was used to determine the values of
SVC. Predicted values (%) were used for statis-
tical analysis.
Phrenic nerve evaluation
Diaphragmatic compound muscle action potential
(CMAP) was elicited bilaterally by percutaneous
bipolar electrical phrenic nerve stimulation at the
neck (posterior to the middle lateral border of the
sternocleidomastoid muscle). Recordings used sur-
face electrodes (with filter setting 20–10 kHz) with
the active electrode (G1) positioned at the homo-
lateral costosternal angle and the reference elec-
trode (G2) at the costal margin 16 cm from the
active electrode, as described elsewhere (10–15);
responses were recorded at the end of expiration
to assure diaphragm relaxation (16). Brachial
plexus responses were avoided by repositioning the
stimulating electrode. A minimum of three consist-
ent motor responses were recorded from each side
and the response with the highest peak-to-peak
amplitude was selected. The mean peak-to-peak
amplitude value (meanPhrenAmpl) of both right-
and left-side responses was used for the analyses,
considered as an inclusion criterion and follow-up
outcome. A cutoff equal or above 0.4mV was
chosen as inclusion criterion for normality, as
mentioned before in the literature (10).
Statistical analysis
The mean percentage of decay between baseline
and week 24 and standard deviation (SD) were
calculated for both SVC and PhrenAmpl. Value at
baseline was normalized to 100%. If there was no
decay the variation was considered as 0%.
Demographics of the population included,
Pearson’s correlations between studied variables,
Student’s t differences between decays were calcu-
lated using SPSSVR 24 IBMVR . A p< 0.05 was con-
sidered as significant.
The sample size was considered as the min-
imum number of patients needed to complete a
24-week randomized parallel controlled trial with
80% power to detect a difference of 30% in the
decay rate (p<0.05) between the placebo and
treatment arms, to be in line with recent clinical
trials (9). Values were pooled using the percentage
of mean and SD decays for SVC and
meanPhrenAmpl in the recruited population, con-
sidered as the placebo arm, with a two-tailed alpha
of 0.05. No additional patients were considered to
compensate for drop-outs.
To calculate the number of patients we applied
the formula (17):
2SD2ðZ1a=2 þ ZpÞ2=
D2ðD ¼ proposed treatment effect differenceÞ:
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Results
We included 317 ALS patients (191 males), with
mean age at disease onset of 59.9±10.7 (31–80)
years, mean BMI at disease onset of 25.48±3.2
(20.1–35) and mean disease duration at study
entry of 10.5±5.6 (1–24) months. The region of
onset was spinal in 225, and bulbar in 92 (29%).
Mean ALSFRS-R at study entry was 41.54±4.3
(22–47) and mean RofALSFRS-R was
11.83±0.38 (11–12).
At study entry, meanPhrenAmpl
(0.65±0.20mV, range 0.40–1.50mV, Figure 1)
was weakly but significantly correlated with SVC
(96.18±15.2%, range 70–160%, Figure 1),
r¼0.18, p¼ 0.002 (Figure 2). MeanPhrenAmpl
decayed 3.6±4.0%/month and 16.94±16.45%/24
weeks, while SVC decayed 2.4±3.15%/month and
13.5±16.86%/24 weeks (Figure 3). A significant
weak correlation between monthly decay of the
two variables was found (r¼ 0.22, p¼0.003,
Figure 2).
A number of 174 patients would be necessary
to recruit using meanPhrenAmpl decay as the
primary outcome, and 272 using mean SVC
decline as the primary outcome measurement.
Discussion
In this study supported by data from a population
of ALS patients eligible for a clinical trial and con-
sidering respiratory function as the main treatment
outcome (9), phrenic nerve responses at baseline
and its monthly decay were significantly but
weakly correlated with SVC values. The weak cor-
relation found can be explained by the different
physiological nature of the tests, since phrenic
nerve responses give specific information on the
diaphragmatic strength, while SVC mainly evalu-
ates the expiratory function but is also dependent
on a full inspiration (5).
Using phrenic nerve amplitude as an inclusion
criterion required the recruitment of a lower num-
ber of patients (98 patients less). This would lead
to shorter inclusion periods, shorter length dur-
ation of the studies and lower costs regarding time
and resources. Taking into account that phrenic
nerve studies is a non-volitional test, not depend-
ent on bulbar function or cognition, we could
anticipate a lower rate of missing values.
Moreover, when the respiratory function is poor,
recording motor responses from the diaphragm is
feasible (10), and the results are symmetric (13),
reliable (12,14), reproducible (18), with an intra-
rater variability of 10% in healthy subjects and
also in patients with primary lateral sclerosis (12),
and a test tolerability close to 100% in our experi-
ence. Its values decay overtime (14,18), but are
feasible until there is marked respiratory involve-
ment and intolerance to supine position.
Figure 1. (A) MeanPhrenAmpl at study entry and 6 months
after (values are presented in mV); (B) SVC at study entry and
6 months after (values are presented in percentage of the
predicted value).
Figure 2. Monthly correlation between SVC and
MeanPhrenAmpl.
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There has been a clear growth in the number
of clinical trials in ALS for the last 25 years, which
have explored new outcomes for testing com-
pound’s effect. Survival has been used as the pri-
mary outcome in many ALS trials. However, it
depends on life-extending interventions and gives
poor information about functionality. Moreover,
survival is not the ideal solution for exploratory
clinical trials since many patients are recruited,
and trials are lengthy and expensive (19).In some
trials ALSFRS-R is preferred as the primary out-
come, reducing trial duration and sample size.
However, ALSFRS-R does not follow a linear
decline, depends on patient judgment, and is influ-
enced by cognitive function (20). RFT are critical
in ALS, since the respiratory function (as eval-
uated by FVC/SVC, and maximal pressures) is a
major prognostic factor (21). Some trials have
selected FVC/SVC as the primary outcome,
according to drug action and the importance of
respiratory function (9). Respiratory function
involvement has also been used as an inclusion cri-
terion in different trials (5,22). SVC was used in
our study, although FVC has traditionally been
used to assess respiratory function in ALS. SVC
and FVC have been shown to be strongly corre-
lated (23) and similarly predictive of survival (24)
and functionality (25) in ALS. However, the
results of the conventional RFT depend on the
bulbar function, cognition and cooperation of
patients (5). In addition, in situations like the
COVID-19 pandemic, it is challenging to maintain
regular RFT evaluation. In our center, phrenic
nerve responses are regularly assessed in ALS
patients and gain particular relevance in those with
moderate-severe orofacial paresis, cognitive
involvement or unable to cooperate with the
respiratory manoeuvers. A cutoff of 0.4mV has
previously been determined as the lower limit of
normality for the peak-to-peak amplitude of the
diaphragmatic responses by phrenic nerve stimula-
tion (10). We use this cutoff as a good indicator of
diaphragmatic weakness and to start NIV in add-
ition to the presence of respiratory symptoms and
the other respiratory measurements (3), being a
very decisive factor in the presence of orofacial
paresis and poor cooperation. The COVID-19
pandemic is also a unique situation during which
phrenic nerve studies can continue being per-
formed without the risk of aerosolization. The
same stands true for nocturnal pulsed oximetry,
which can complement the information whenever
needed. In the design of early-phase trials in ALS,
the introduction of predictive or prognostic bio-
markers is an important step (22). In this regard,
to explore phrenic nerve study as a surrogate
marker of respiratory function in ALS seems a
good option.
We should be cautious on our results because
sample size calculation depends on a large array of
assumptions. Inter-rater reliability and the
expected number of patients to be lost during fol-
low-up were, for example, not considered in our
study. Anyhow, in any trial, a previous training on
the measurements used is a rule. Standard operat-
ing procedures (SOPs) should be detailed,
addressing technical issues, such as type of electro-
des, filters, stimulus parameters, as well as the cor-
rect positioning of the electrodes, stimulus timing,
identification of artifacts, correct recording of the
motor responses and selection of the best consist-
ent responses. SOPs, training and intra-rater and
inter-rater variability studies have been carried out
for other neurophysiological techniques, namely
for motor unit number index (MUNIX) (26),
Figure 3.. Percentage of SVC and MeanPhrenAmpl decay at
month 6 (A) and correlation between both variables at month
6 (B).
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which could be easily adapted and replicated for
the phrenic studies.
We conclude that phrenic nerve study should
be considered in future trials as an option for the
inclusion and follow-up of ALS patients.
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